Palvella Therapeutics (NASDAQ:PVLA) Sets New 52-Week High After Analyst Upgrade

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) reached a new 52-week high during mid-day trading on Tuesday after Mizuho raised their price target on the stock from $205.00 to $250.00. Mizuho currently has an outperform rating on the stock. Palvella Therapeutics traded as high as $127.69 and last traded at $124.45, with a volume of 470889 shares traded. The stock had previously closed at $87.84.

Several other equities research analysts also recently weighed in on PVLA. HC Wainwright raised their price target on shares of Palvella Therapeutics from $200.00 to $255.00 and gave the company a “buy” rating in a research report on Tuesday. UBS Group reiterated a “buy” rating and issued a $143.00 price target on shares of Palvella Therapeutics in a research report on Monday, December 15th. Craig Hallum assumed coverage on shares of Palvella Therapeutics in a report on Thursday, December 4th. They issued a “buy” rating and a $175.00 target price for the company. Weiss Ratings reissued a “sell (d)” rating on shares of Palvella Therapeutics in a report on Monday, December 29th. Finally, Cantor Fitzgerald increased their price objective on shares of Palvella Therapeutics from $120.00 to $200.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $176.44.

Insider Transactions at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total transaction of $420,004.26. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 20.50% of the stock is owned by corporate insiders.

Key Headlines Impacting Palvella Therapeutics

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Positive Phase 3 SELVA topline results for QTORIN™ 3.9% rapamycin — a clinical win materially increases the program’s regulatory and commercial outlook and is the primary driver of the stock rally. Palvella Therapeutics Announces Positive Topline Results
• Positive Sentiment: Multiple analysts raised price targets and estimates (H.C. Wainwright to $255, Mizuho to $250, BTIG to $215, Chardan to $210) and H.C. Wainwright materially upgraded multi-year EPS forecasts — these actions amplify bullish sentiment and institutional demand. H.C. Wainwright Price Target Raise
• Neutral Sentiment: Palvella priced an upsized public offering of 1.6M shares at $125 to raise about $200M (with a 30‑day option for +240k shares) to fund development of QTORIN programs and general corporate needs — this materially strengthens the company’s cash runway but will add shares outstanding when closed. Pricing of Upsized Public Offering
• Neutral Sentiment: Short interest rose (~17.8% of float, days-to-cover ~5.5) in February — this can amplify intraday moves (both upward via squeeze dynamics and downward via short pressure) and adds volatility risk for traders.
• Negative Sentiment: All offering shares are being sold by Palvella (not insiders), so the new issuance will dilute existing holders; reported insider sales (COO sales disclosed) may also concern some investors about near-term insider sentiment. Quiver Quant Offering Summary

Institutional Investors Weigh In On Palvella Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Invesco Ltd. boosted its position in shares of Palvella Therapeutics by 11.6% during the fourth quarter. Invesco Ltd. now owns 54,273 shares of the company’s stock worth $5,681,000 after buying an additional 5,663 shares during the period. XTX Topco Ltd purchased a new position in Palvella Therapeutics in the fourth quarter valued at approximately $429,000. Virtus Investment Advisers LLC purchased a new stake in Palvella Therapeutics in the fourth quarter valued at $282,000. Superstring Capital Management LP acquired a new stake in shares of Palvella Therapeutics in the 4th quarter valued at about $2,666,000. Finally, Suvretta Capital Management LLC increased its holdings in shares of Palvella Therapeutics by 8.5% in the 4th quarter. Suvretta Capital Management LLC now owns 892,400 shares of the company’s stock valued at $93,408,000 after acquiring an additional 70,000 shares during the period. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Price Performance

The firm’s 50 day moving average price is $92.78 and its two-hundred day moving average price is $78.86. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of -55.88 and a beta of -0.16.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.